Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S2468-1253(24)00123-7 | DOI Listing |
Lancet Gastroenterol Hepatol
July 2024
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, Jiangsu, China. Electronic address:
Lancet Gastroenterol Hepatol
July 2024
Institut Pasteur, Université Paris Cité, Unité d'Épidémiologie des Maladies Émergentes, Paris 75015, France. Electronic address:
Lancet Reg Health West Pac
June 2024
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Lancet Gastroenterol Hepatol
April 2024
Hepato-Gastroenterology Department, Yalgado Ouédraogo University Hospital Center, Ouagadougou, Burkina Faso.
Background: Hepatitis B virus (HBV) elimination requires expanding and decentralising HBV care services. However, peripheral health facilities lack access to diagnostic tools to assess eligibility for antiviral therapy. Through the Hepatitis B in Africa Collaborative Network (HEPSANET), we aimed to develop and evaluate a score using tests generally available at lower-level facilities, to simplify the evaluation of antiviral therapy eligibility in people living with HBV.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!